<DOC>
	<DOCNO>NCT01964716</DOCNO>
	<brief_summary>This study compare immune response infant give 13vPnC mutidose vial formulation immune reponses infant give 13vPnC single-dose syringe formulation . It also evaluate safety 13-valent pneumococcal conjugate vaccine ( 13vPnC ) infant vaccinate .</brief_summary>
	<brief_title>13vPnC Multidose Vial Safety , Tolerability Immunogenicity Study Healthy Infants .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 42 70 day enrollment . Determined medical history , physical examination , clinical judgment eligible study Weight 3.5 kg great time enrollment Previous vaccination license investigational pneumococcal vaccine . A previous anaphylactic reaction vaccine vaccinerelated component . Contraindication vaccination pneumococcal conjugate vaccine . Receipt blood product gammaglobulin since birth</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>70 Days</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Prevenar 13</keyword>
	<keyword>13vPnC</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>